Ingen appoints director of r&d

Aims to increase sales of in vitro diagnostic (IVD) kits

Ingen Biosciences, a French developer of advanced in vitro diagnostic kits for clinical use, has appointed Karine Mignon-Godefroy as director of research & development.

Mignon-Godefroy joins the firm to generate sales of its first proprietary in vitro diagnostic (IVD) kit. These IVD kits are based on the firm’s specialist knowledge in proteomics and expertise in synthesising new recombinant antigens. Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens as potential markers for the detection of infectious diseases found in prosthetic replacements, and to develop innovative IVD kits for clinical use.

‘Dr Mignon-Godefroy’s 15 years’ experience in biotechnology, depth of knowledge and skills will be a major contribution to our on-going r&d efforts,’ said Jean-Pierre Hermet, chief executive of Ingen Biosciences. ‘Her arrival will also strengthen the team, which has made significant inroads into developing products based on innovative technologies.'

Mignon-Godefroy joins Ingen Biosciences from the blood virus division of Bio-Rad, a manufacturer and distributor of products for a range of technologies including proteomics, where she was director of international projects.

You may also like

Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Manufacturing

Cellevate achieves ISO 9001:2015 certification alongside GMP production processes in new cleanroom

The certification caps off a strong 2025 for the company, which now has a scalable foundation for expanding manufacturing capacity and implementing GMP-ready processes for commercial volumes
Manufacturing

LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener

Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Regulatory

Grifols gets nod from European Medicines Agency for entire value chain of Grifols Egypt

The institution's certification endorses the entire plasma value chain under the highest European standards and opens the door for Egypt to, once domestic needs are met, export to other markets including Europe
Regulatory

Regulating innovation: a new focus on digital mental health technologies (DMHTs)

IMed Consultancy’s Benjamin Austin provides a clear understanding of how digital mental health technologies are innovating care and describes the evolving regulatory frameworks that ensure their safety and effectiveness
Regulatory

ten23 health QC lab to support commercial product testing for US customer following FDA approvals

This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to manufacturing the commercial product
Subscribe now